Latest News From "The Pink Sheet" DAILY - BMS Ends Deal With Exelixis

Exelixis Defends Cancer Drug XL184 After Partner BMS Walks Out

After spending $257 million and pushing into Phase III trials for a rare thyroid cancer, Bristol-Myers Squibb ends its deal. Exelixis CEO George Scangos says: "There is no smoking gun."   read more

 

FDA Endpoint Development For Pediatric Pulmonary Arterial Hypertension Focuses On Pfizer's Revatio

The standard exercise test is a problem for many pediatric patients, and FDA's Cardiovascular and Renal Drugs Advisory Committee will assess alternatives.   read more

 

Mylotarg Pulled Off Market, But Pfizer Continues Search For Appropriate Population

After a futile confirmatory trial, Pfizer will review ongoing studies to see if they can be refined to indentify patients that could benefit from the drug, oncology VP Eagle says.   read more

 

Affymax's Share Price Stumbles On Questionable Phase III Hematide Data

Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.   read more

 

European Price Cuts Likely To Be Above Normal This Year, Says EFPIA President Witty

GSK's Witty urges European companies to work with government payers.   read more

 

Tax Benefits Highlight Announced Merger Of Valeant And Biovail

A deal that would combine two smaller specialty pharmas into one will result in a company with four main business areas.   read more

 

Supreme Court Declines To Review Wyeth Product Liability Suit, Ortho Whistleblower Case

Wyeth challenged whether testimony of expert witness in hormone replacement therapy litigation was admissible; Ortho Biotech argued former sales rep was not an original source of kickback claims.   read more

 

Whole-Genome Sequencing Is Here, But Clinical Utility Remains Unproven

Multiple firms are racing to develop an affordable whole-genome sequencing product as a marketable diagnostics tool, but clinicians and genetics experts told a government advisory panel last week that the practice is not yet ready for clinical application   read more

"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here